Barcelona, Spain – 29 Aug 2017: Poor sleep is associated with ischaemic heart disease and stroke, according to research presented today at ESC Congress. (1) The observational study in nearly 13 000 people revealed different patterns of sleep disturbance between the two conditions, with ischaemic heart disease being linked to shorter sleep and brief moments of waking up.
“Poor sleep is associated with cardiovascular diseases such as ischaemic heart disease and stroke but the kind of sleep disturbances that are most risky is not well documented,” said lead researcher Dr Nobuo Sasaki, of the Hiroshima Atomic Bomb Casualty Council, Japan. (2), (3) “‘Poor sleep’ includes too short or too long sleep, difficulty falling asleep, and difficulty maintaining sleep.”
This study investigated the association between sleep disturbances and cardiovascular disease. It also aimed to clarify possible differences in sleep disturbances between ischaemic heart disease and stroke.
The study included 12 876 residents of Hiroshima, Japan (6 762 men and 6 114 women, average age 68 years) who were registered for an annual health check. Of those, 773 patients had a history of ischaemic heart disease (myocardial infarction and/or angina), 560 patients had a history of stroke (intracranial haemorrhagic and/or cerebral infarction), and 11 543 had no cardiovascular disease. Patients with both ischaemic heart disease and stroke, or another type of cardiovascular disease, were excluded from the study.
Sleep habits were assessed with the Pittsburgh Sleep Quality Index (PSQI), a 19-item self-reporting questionnaire which yields seven component scores. C1 assesses subjective poor sleep quality, C2 long sleep latency, C3 short sleep duration, C4 low sleep efficiency, C5 difficulty in maintaining sleep, C6 use of sleeping pills, and C7 daytime dysfunction. Each component is ranked 0, 1, 2, or 3, with a score ≥ 2 defining sleep disturbance (except C6 score ≥ 1).
A sum of the seven scores was used to calculate the global PSQI score which ranged from 0 to 21. Higher scores indicated poorer sleep quality, and ‘poor sleep’ was defined as a global PSQI score ≥ 6.
Rates of ‘poor sleep’ and component sleep disturbances are shown in figures A and B. Poor sleep occurred in 52%, 48%, and 37% of patients with ischaemic heart disease, stroke, and no cardiovascular disease, respectively.
After adjusting for confounding factors (table) ‘poor sleep’ was significantly associated with ischaemic heart disease (odds ratio [OR], 1.71; p <0.0001) and stroke (OR, 1.45; p <0.0001). Component analysis revealed that subjective poor sleep quality (C1), long sleep latency (C2), low sleep efficiency (C4), and use of sleeping pills (C6) were significantly associated with both ischaemic heart disease and stroke. Difficulty maintaining sleep (C5), short sleep duration (C3), and daytime dysfunction (C7) were associated only with ischaemic heart disease (table).
Dr Sasaki said: “The proportion of people suffering from sleep disturbances is around 1.5-fold higher among patients with previous ischaemic heart disease or stroke compared to those with no history of cardiovascular disease.”
“Interestingly only patients with ischaemic heart disease reported difficulty maintaining sleep and short sleep duration,” he continued. “Difficulty maintaining sleep reflects an increase in sleep fragmentation, which refers to brief moments of waking up and causes overactivity of the sympathetic nervous system and adrenocortical axis.” (4)
Dr Sasaki concluded: “Our results support the hypothesis that sleep deterioration may lead to cardiovascular disease. Poor sleep in patients with ischaemic heart disease may be characterised by shorter sleep and brief moments of waking up.”
Figure A: Poor sleep
Proportion of poor sleep in ischaemic heart disease (IHD), stroke, and non-cardiovascular disease (CVD) populations. Poor sleep was defined as a global Pittsburgh Sleep Quality Index score of 6 or more.
Figure B: Sleep componentsProportions of subjective sleep quality (C1), long sleep latency (C2), short sleep duration (C3), low sleep efficiency (C4), difficulty maintaining sleep (C5), use of sleeping pills (C6), and daytime dysfunction (C7) in ischaemic heart disease (IHD), stroke, and non-cardiovascular disease (CVD) populations. Each type of disturbed sleep was defined as a score ≥ 2 (except C6 score ≥ 1).
Data adjusted for age, gender, body mass index, smoking, alcohol intake, and presence of hypertension, diabetes, and dyslipidaemia.Key: Ischaemic heart disease (IHD), odds ratio (OR), confidence interval (CI).
Sources of funding: This study has not received any financial support.
References and notes(1) The abstract “Poor sleep and cardiovascular disease: different pattern of sleep disturbance in ischemic heart disease and stroke” will be presented during:• The press conference Living longer: tips and tricks on Sunday 27 August from 9:00 to 10:00.• Poster session 7: Prevention general on Tuesday 29 August from 14:00 to 18:00 in the Poster Area.(2) Cappuccio FP, et al. Sleep duration predicts cardiovascular outcomes: a systematic review and meta-analysis of prospective studies. Eur Heart J. 2011;32:1484–1492.(3) Sivertsen B, et al. Insomnia as a risk factor for ill health: results from the large population-based prospective HUNT Study in Norway. J Sleep Res. 2014;23:124–132.(4) Chouchou F, et al. Sympathetic overactivity due to sleep fragmentation is associated with elevated diurnal systolic blood pressure in healthy elderly subjects: the PROOF-SYNAPSE study. Eur Heart J. 2013; 34:2122–2131.
ESC Press OfficeFor more information, please contact the ESC Press Office: email@example.com.For press enquiries, independent comment on-site, please contact, the Media & Press Coordinator Jacques Olivier COSTA: +34 666 509 856The press conference timetable is available here.
To access all the scientific resources from the sessions during the congress, visit ESC Congress 365. About the European Society of CardiologyThe European Society of Cardiology brings together health care professionals from more than 140 countries, working to advance cardiovascular medicine and help people lead longer, healthier lives.About ESC Congress 2017ESC Congress is the world’s largest and most influential cardiovascular event contributing to global awareness of the latest clinical trials and breakthrough discoveries. ESC Congress 2017 takes place 26 to 30 August at the Fira Gran Via in Barcelona, Spain. The scientific programme is here. More information is available from the ESC Press Office at firstname.lastname@example.org.This press release accompanies both a presentation and an ESC press conference at the ESC Congress 2017. Edited by the ESC from material supplied by the investigators themselves, this press release does not necessarily reflect the opinion of the European Society of Cardiology. The content of the press release has been approved by the presenter.
Our mission: To reduce the burden of cardiovascular disease
© 2018 European Society of Cardiology. All rights reserved